Trading

Why is Aclaris Therapeutics Stock Trading Lower on Monday?

Summary

Aclaris Therapeutics stock fell following the release of disappointing results from a mid-stage skin disease trial. Despite missing the main study goals, company leadership stated that development priorities and future timelines for key drug programs remain unchanged.

Aclaris Therapeutics Inc. (NASDAQ:ACRS) CEO Neal Walker affirmed on Monday that the clinical-stage biopharmaceutical company will maintain its core development priorities despite missing primary and secondary endpoints in a Phase 2 atopic dermatitis study. Walker emphasized that Aclaris remains committed to advancing its oral kinase inhibitors and bispecific antibody programs toward major clinical and regulatory milestones throughout 2027. Bosakitug Misses…

Source: Read the full story at Top Stories Feed

Follow Tech & Money Press for daily watchlists and market news

XFacebookInstagramTikTok
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.
About UsContactPrivacy PolicyDisclaimer
Not financial advice. Curated headlines link to their original publishers.